The approval of Eylea 8 mg (aflibercept 8 mg) in China for the treatment of wet age-related macular degeneration (AMD) comes following the positive results of the phase 3 PULSAR trial, which demonstrated that 8mg had comparable efficacy and safety with dosing intervals extended to Q12 or Q16 weeks compared to standard Eylea 2mg administered every 8 weeks.
Eylea 8mg offers a more durable alternative treatment, reducing the burden of clinic visits and injections while also maintaining vision and functional outcomes.
Read more here:
